Technical Analysis for FUSN - Fusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
B 21.32 0.09% 0.02
FUSN closed up 0.09 percent on Thursday, March 28, 2024, on 65 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 100.38%
New Uptrend Bullish 100.38%
Pocket Pivot Bullish Swing Setup 100.38%
Bullish Engulfing Bullish 113.41%
Earnings Movers Other 113.41%
Multiple of Ten Bearish Other 113.41%
Wide Bands Range Expansion 113.41%
Oversold Stochastic Weakness 113.41%
Narrow Range Bar Range Contraction 128.27%
Earnings Movers Other 128.27%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fusion Pharmaceuticals Inc. Description

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Clinical Development Antibodies Tumor Cell Biology Insulin Precision Medicine Tyrosine Kinase Receptors Bladder Cancer Checkpoint Inhibitor Proteins Fibroblast Growth Factor Fibroblast Growth Factor Receptor Radiopharmaceuticals Growth Factor Pharmacodynamics

Is FUSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.44
52 Week Low 2.31
Average Volume 2,395,405
200-Day Moving Average 6.48
50-Day Moving Average 12.63
20-Day Moving Average 14.57
10-Day Moving Average 19.04
Average True Range 0.98
RSI (14) 83.39
ADX 48.18
+DI 56.86
-DI 9.42
Chandelier Exit (Long, 3 ATRs) 18.50
Chandelier Exit (Short, 3 ATRs) 12.03
Upper Bollinger Bands 25.50
Lower Bollinger Band 3.65
Percent B (%b) 0.81
BandWidth 149.96
MACD Line 2.87
MACD Signal Line 1.97
MACD Histogram 0.8972
Fundamentals Value
Market Cap 1.54 Billion
Num Shares 72.4 Million
EPS -1.61
Price-to-Earnings (P/E) Ratio -13.24
Price-to-Sales 370.88
Price-to-Book 4.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.50
Resistance 3 (R3) 21.50 21.43 21.47
Resistance 2 (R2) 21.43 21.39 21.44 21.46
Resistance 1 (R1) 21.38 21.36 21.41 21.38 21.45
Pivot Point 21.31 21.31 21.33 21.32 21.31
Support 1 (S1) 21.26 21.27 21.29 21.26 21.19
Support 2 (S2) 21.19 21.24 21.20 21.18
Support 3 (S3) 21.14 21.19 21.17
Support 4 (S4) 21.14